Background: The SYNERGY Study is an observational, multicenter Italian study, conducted in patients with diagnosis of psoriatic arthritis (PsA) treated from at least 3 months with cyclosporine and aimed at assessing patients' seropositivity for viral infections and efficacy and safety of cyclosporine, administered as monotherapy or in combination with other systemic drugs in the routine clinical practice. The aim of this subanalysis of the SYNERGY study was to evaluate the effects of CsA as monotherapy only in PsA over 12 months of observation.
Methods: Psoriasis was evaluated by Body Surface Area and the Psoriasis Area Severity Index (PASI). PsA was evaluated by number of swollen and tender joints, painful entheses and fingers with dactylitis, the Bath Ankylosing Spondylitis Activity Index (BASDAI) and by patients' and physicians' global assessment on a 10-point Visual Analogue Scale.
Results: Cyclosporine in monotherapy was effective in reducing all the measured disease parameters. The major indexes of cutaneous and spinal involvement, PASI and BASDAI were significantly reduced over the study period, as were the number of swollen and tender peripheral joints, and enthesitis and dactylitis.
Conclusions: Cyclosporine in monotherapy confirmed its efficacy in cutaneous psoriasis and suggested to be effective also on PsA, reducing spinal and peripheral joints' signs and symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23736/S0392-0488.16.05301-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Potential of Combined 5% Lifitegrast and Tocopherol Eye Drops in Managing Inflammation and Oxidative Stress in Murine Dry Eye.
Pharmaceuticals (Basel)
January 2025
Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea.
: This study aimed to evaluate the therapeutic effects of combined 5% lifitegrast (LF) and tocopherol (TCP) eye drops in a murine experimental dry eye (EDE) model. Female C57BL/6 were divided into seven groups: untreated controls, EDE control, EDE + 0.05% cyclosporin A (CsA), EDE + tocopherol (TCP), EDE + 5% LF, EDE + 5% LF + TCP (once daily), and EDE + 5% LF + TCP (twice daily).
View Article and Find Full Text PDFA multicentre, retrospective study of epidemiology and outcome of aplastic anaemia among adult population in Sabah and Sarawak from year 2006 to 2017.
Med J Malaysia
November 2024
Queen Elizabeth Hospital, Department of Medicine, Haematology Unit, Sabah, Ministry of Health, Malaysia.
Introduction: Aplastic anaemia (AA) is a rare disorder of bone marrow failure, characterized by bone marrow hypocellularity with pancytopenia. The annual incidence rates of AA in Asia are observed to be two to three times higher than Europe and North America. Since the introduction of immunosuppressive therapy (IST) and of allogenic stem cell transplant (SCT), the outcome of severe AA has significantly improved.
View Article and Find Full Text PDFMaintenance immunosuppressive therapy in liver transplantation: results from CESIT study, an Italian retrospective cohort study.
BMJ Open
November 2024
Department of Epidemiology, Lazio Regional Health Service, Roma, Lazio, Italy
Objectives: To investigate the use of maintenance immunosuppressive treatments following liver transplantation and to compare their risk-benefit profiles in clinical practice.
Design: Retrospective multicentrer cohort study.
Setting: Four Italian regions (Lombardy, Veneto, Lazio, Sardinia).
Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study.
Ann Med
December 2024
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.
Article Synopsis
- - The study focuses on elderly patients (60+) with transfusion-dependent non-severe aplastic anemia (TD-NSAA), who have limited treatment options due to compatibility and safety issues.
- - Researchers compared two treatment regimens: avatrombopag (AVA) plus cyclosporine (CsA) and CsA alone, finding a notably higher overall response rate and complete response rate in those receiving AVA + CsA.
- - The combination treatment also led to quicker responses and greater independence from platelet transfusions, suggesting it is a promising option for elderly patients with TD-NSAA.
2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore.
Ann Acad Med Singap
September 2024
Dr SN Wong Skin, Hair, Nails & Laser Specialist Clinic, Singapore.
Article Synopsis
- Psoriasis is a chronic inflammatory skin disease that requires varied management approaches, which the study aimed to standardize through new guidelines tailored for dermatology practice in Singapore.
- A specialized workgroup conducted a comprehensive literature review on psoriasis treatments from 2013 to 2023, refining clinical questions to create practical guidelines covering assessment and management strategies for different severity levels of psoriasis.
- The resulting guidelines suggest various therapies, including both systemic and topical treatments, while addressing specific concerns for special populations and providing recommendations for managing related conditions like psoriatic arthritis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!